Literature DB >> 8307145

Prevalence and incidence of hepatitis C virus infection among male prison inmates in Maryland.

D Vlahov1, K E Nelson, T C Quinn, N Kendig.   

Abstract

To identify incidence of antibody to hepatitis C virus among 265 male prison inmates, we assayed paired serum specimens obtained at intake in 1985-1986 with follow-up specimens in 1987. Intake prevalence was 38 percent. Seroincidence was 1.1/100 person years in prison. This finding might reflect saturation of high-risk subgroups or possibly reduced frequency of exposures following incarceration.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8307145     DOI： 10.1007/BF00209538

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN： 0393-2990            Impact factor:   8.082


  14 in total

1.  Seroepidemiologic study of hepatitis B and C viruses in federal correctional institutions in British Columbia.

Authors:  R G Préfontaine; R K Chaudhary
Journal:  Can Dis Wkly Rep       Date:  1990-12-29

2.  Hepatitis C virus antibody.

Authors:  P P Mortimer; B J Cohen; P A Litton; E M Vandervelde; M F Bassendine; A M Brind; M H Hambling
Journal:  Lancet       Date:  1989-09-30       Impact factor: 79.321

3.  Temporal trends of human immunodeficiency virus type 1 (HIV-1) infection among inmates entering a statewide prison system, 1985-1987.

Authors:  D Vlahov; F Brewer; A Muñoz; D Hall; E Taylor; B F Polk
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1989

4.  Transmission of HIV-1 within a statewide prison system.

Authors:  T F Brewer; D Vlahov; E Taylor; D Hall; A Munoz; B F Polk
Journal:  AIDS       Date:  1988-10       Impact factor: 4.177

5.  Importance of heterosexual activity in the transmission of hepatitis B and non-A, non-B hepatitis.

Authors:  M J Alter; P J Coleman; W J Alexander; E Kramer; J K Miller; E Mandel; S C Hadler; H S Margolis
Journal:  JAMA       Date:  1989-09-01       Impact factor: 56.272

6.  Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis.

Authors:  H J Alter; R H Purcell; J W Shih; J C Melpolder; M Houghton; Q L Choo; G Kuo
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

7.  Antibody to hepatitis C virus in post-transfusion hepatitis.

Authors:  F Tremolada; C Casarin; A Tagger; M L Ribero; G Realdi; A Alberti; A Ruol
Journal:  Ann Intern Med       Date:  1991-02-15       Impact factor: 25.391

8.  The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team.

Authors:  M J Alter; H S Margolis; K Krawczynski; F N Judson; A Mares; W J Alexander; P Y Hu; J K Miller; M A Gerber; R E Sampliner
Journal:  N Engl J Med       Date:  1992-12-31       Impact factor: 91.245

9.  Seroepidemiology of hepatitis B in Tennessee prisoners.

Authors:  M D Decker; W K Vaughn; J S Brodie; R H Hutcheson; W Schaffner
Journal:  J Infect Dis       Date:  1984-09       Impact factor: 5.226

10.  Prevalence of antibody to HIV-1 among entrants to US correctional facilities.

Authors:  D Vlahov; T F Brewer; K G Castro; J P Narkunas; M E Salive; J Ullrich; A Muñoz
Journal:  JAMA       Date:  1991-03-06       Impact factor: 56.272
View more
  19 in total

1.  Health effects of prisons. Many injectors stop injecting while imprisoned.

Authors:  B P Smyth
Journal:  BMJ       Date:  2000-12-02

2.  Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island prisons.

Authors:  Grace E Macalino; David Vlahov; Stephanie Sanford-Colby; Sarju Patel; Keith Sabin; Christopher Salas; Josiah D Rich
Journal:  Am J Public Health       Date:  2004-07       Impact factor: 9.308

3.  Prevalence and correlates of Hepatitis C among injection drug users: The significance of duration of use, incarceration and race/ethnicity.

Authors:  William W Latimer; Sarra L Hedden; Leah Floyd; April Lawson; Alexander Melnikov; S Geoffrey Severtson; Anne-Gloria Moleko; Kristin Cole
Journal:  J Drug Issues       Date:  2009-09

4.  Provision of syringes: the cutting edge of harm reduction in prison?

Authors:  J Nelles; A Fuhrer; H Hirsbrunner; T Harding
Journal:  BMJ       Date:  1998-07-25

5.  The burden of infectious disease among inmates of and releasees from US correctional facilities, 1997.

Authors:  Theodore M Hammett; Mary Patricia Harmon; William Rhodes
Journal:  Am J Public Health       Date:  2002-11       Impact factor: 9.308

6.  Prevalence of hepatitis C virus infection and its related risk factors in drug abuser prisoners in Hamedan--Iran.

Authors:  Amir Houshang Mohammad Alizadeh; Seyed Moayed Alavian; Khalil Jafari; Nastaran Yazdi
Journal:  World J Gastroenterol       Date:  2005-07-14       Impact factor: 5.742

7.  Prevalence and correlates of hepatitis C virus infection among inmates entering the California correctional system.

Authors:  J D Ruiz; F Molitor; R K Sun; J Mikanda; M Facer; J M Colford; G W Rutherford; M S Ascher
Journal:  West J Med       Date:  1999-03

8.  Feasibility and outcome of HCV treatment in a Canadian federal prison population.

Authors:  John Farley; Shawn Vasdev; Benedikt Fischer; Emma Haydon; Jürgen Rehm; Theresa A Farley
Journal:  Am J Public Health       Date:  2005-08-30       Impact factor: 9.308

9.  Incidence and risk for acute hepatitis C infection during imprisonment in Australia.

Authors:  Kate Dolan; Suzy Teutsch; Nicolas Scheuer; Michael Levy; William Rawlinson; John Kaldor; Andrew Lloyd; Paul Haber
Journal:  Eur J Epidemiol       Date:  2010-02       Impact factor: 8.082

10.  Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study.

Authors:  I van Beek; R Dwyer; G J Dore; K Luo; J M Kaldor
Journal:  BMJ       Date:  1998-08-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.